ALZpath announced the first large‑scale study using a pTau217 blood assay (Simoa® ALZpath pTau217) to detect Alzheimer’s disease early and at population scale. The study represents a landmark deployment of a plasma phospho‑tau biomarker that is being positioned for screening and epidemiologic surveillance. Separately, Siemens Healthineers licensed ALZpath’s pTau217 antibody to develop blood‑based diagnostics for Alzheimer’s, joining Roche and Beckman Coulter in commercial partnerships. Siemens’ involvement signals continued industry consolidation around plasma tau assays as they move from research into clinical diagnostics. Together, the ALZpath study and Siemens deal mark a commercialization inflection for blood‑based AD diagnostics and will influence clinical trial enrollment, primary‑care screening pathways, and the nascent market for neurodegenerative biomarkers.